Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, Kenneth J. Gorelick et al.|The Lancet|2017Cited by 198
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA studyWilliam J. Sandborn, Geert D’Haens, Scott D. Lee et al.|Gut|2017Cited by 107
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA StudyGeert D’Haens, Olaf Stüve, Séverine Vermeire et al.|Journal of Crohn s and Colitis|2017Cited by 28
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT StudyWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2015Cited by 26
Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s DiseaseMina Hassan‐Zahraee, Kenneth E. Hung, Anindita Banerjee et al.|Journal of Crohn s and Colitis|2017Cited by 26